Drug Trial Radar · NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6,452
Planned (sponsor's estimate)
Start
Aug 17, 2015
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Conditions
- Advanced Lymphoma
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- Cervical Carcinoma
- Colon Carcinoma
- Colorectal Carcinoma
- Endometrial Carcinoma
- Esophageal Carcinoma
- Exocrine Pancreas Carcinoma
- Gastric Carcinoma
- Glioma
- Head and Neck Carcinoma
- Hematopoietic and Lymphoid Cell Neoplasm
- Kidney Carcinoma
- Liver Carcinoma
- Lung Carcinoma
- Lymphoma
- Malignant Uterine Corpus Neoplasm
- Malignant Uterine Neoplasm
- Melanoma
- Multiple Myeloma
- Ovarian Carcinoma
- Prostate Carcinoma
- Rectal Carcinoma
- Recurrent Bladder Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Colon Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Glioma
- Recurrent Head and Neck Carcinoma
- Recurrent Liver Carcinoma
- Recurrent Lung Carcinoma
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Malignant Uterine Corpus Neoplasm
- Recurrent Melanoma
- Recurrent Multiple Myeloma
- Recurrent Ovarian Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Prostate Carcinoma
- Recurrent Rectal Carcinoma
- Recurrent Skin Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Multiple Myeloma
- Skin Carcinoma
- Thyroid Gland Carcinoma
Interventions
AdavosertibDrug
Given PO
AfatinibDrug
Given PO
Afatinib DimaleateDrug
Given PO
BinimetinibDrug
Given PO
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
CapivasertibDrug
Given PO
Computed TomographyProcedure
Undergo computed tomography (CT)
CopanlisibDrug
Given IV
Copanlisib HydrochlorideDrug
Given IV
CrizotinibDrug
Given PO
Cytology Specimen Collection ProcedureOther
Optional correlative studies
DabrafenibDrug
Given PO
Dabrafenib MesylateDrug
Given PO
DasatinibDrug
Given PO
DefactinibDrug
Given PO
Defactinib HydrochlorideDrug
Given PO
Echocardiography TestProcedure
Undergo echocardiography (ECHO)
ErdafitinibDrug
Given PO
FexagratinibDrug
Given PO
IpatasertibDrug
Given PO
Laboratory Biomarker AnalysisOther
Undergo molecular analysis
LarotrectinibDrug
Given PO
Larotrectinib SulfateDrug
Given PO
Magnetic Resonance ImagingProcedure
Undergo magnetic resonance imaging (MRI)
Multigated Acquisition ScanProcedure
Undergo MUGA
NivolumabBiological
Given IV
OsimertinibDrug
Given PO
PalbociclibDrug
Given PO
PertuzumabBiological
Given IV
PI3K-beta Inhibitor GSK2636771Drug
Given PO
Radiologic ExaminationProcedure
Undergo radiologic evaluation
Radionuclide ImagingProcedure
Undergo nuclear study
RelatlimabBiological
Given IV
SapanisertibDrug
Given PO
Sunitinib MalateDrug
Given PO
TaselisibDrug
Given PO
TrametinibDrug
Given PO
TrastuzumabBiological
Given IV
Trastuzumab EmtansineBiological
Given IV
UlixertinibDrug
Give PO
VismodegibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to 3 years
Locations
1,410 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
Thomas Hospital
Fairhope, Alabama
Mobile Infirmary Medical Center
Mobile, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Regional Hospital
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
CTCA at Western Regional Medical Center
Goodyear, Arizona
Kingman Regional Medical Center
Kingman, Arizona
Cancer Center at Saint Joseph's
Phoenix, Arizona
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona
Mayo Clinic Hospital in Arizona
Phoenix, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona
Mercy Hospital Fort Smith
Fort Smith, Arkansas
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
Kaiser Permanente-Deer Valley Medical Center
Antioch, California
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Eden Hospital Medical Center
Castro Valley, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
Showing 40 of 1,410 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.